Pfizer (PFE) Tops Q2 EPS by 10c; Narrows FY Revenue Guidancce
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Pfizer Reports Second-Quarter 2023 Results
August 1, 2023 6:45 AM EDTSecond-Quarter 2023 Revenues of $12.7 Billion Expected Decline in Paxlovid and Comirnaty(1) Revenues Drove 53% Operational Decrease in Second-Quarter 2023 Revenues Second-Quarter 2023 Revenues from Comirnaty(1) and Paxlovid of $1.6 Billion Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew 5% Operationally Second-Quarter 2023 Reported Diluted EPS(2) of $0.41, a Year-Over-Year Decline of 77%, and Adjusted Diluted EPS(3) of $0.67, a Year-Over-Year Decline of 67% Narrows 2023 Revenue Guidance(4) Range to $67 to $70 Billion and Adjusts 2023 Non-COVID Operational Revenue Growth Expectation to 6% to 8% Maintains All Other Components of Full-Year 2023 Financial Guidance(4), Including Guidance for Adjusted Diluted... More
